Polymyositis and dermatomyositis secondary prevention
|
Polymyositis and dermatomyositis Microchapters |
|
Differentiating Polymyositis and dermatomyositis from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Polymyositis and dermatomyositis secondary prevention On the Web |
|
American Roentgen Ray Society Images of Polymyositis and dermatomyositis secondary prevention |
|
FDA on Polymyositis and dermatomyositis secondary prevention |
|
CDC on Polymyositis and dermatomyositis secondary prevention |
|
Polymyositis and dermatomyositis secondary prevention in the news |
|
Blogs on Polymyositis and dermatomyositis secondary prevention |
|
Risk calculators and risk factors for Polymyositis and dermatomyositis secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sadaf Sharfaei M.D.[2]
Overview
Effective measures for the secondary prevention of [disease name] include [strategy 1], [strategy 2], and [strategy 3].
Secondary Prevention
- Effective measures for the secondary prevention of polymyositis and dermatomyositis include:[1]
- Regular follow
- Malignancy screening
- Effective measures for assessing malignancy in patients with polymyositis and dermatomyositis include:
- Initially and annually diagnostic studies for three years including:[2]
- Chest CT scan
- Abdomen CT scan
- Pelvic CT scan
- Gynecologic examination and pelvic/transvaginal ultrasonogram
- It is controversial to use tumor markers as a screening test for malignancy.
- Initially and annually diagnostic studies for three years including:[2]
- Effective measures for assessing malignancy in patients with polymyositis and dermatomyositis include:
- Pulmonary protectionup
- Lifestyle modification including:
- Physical therapy and exercise
- Healthy and well-balanced diet
- Watching weight
- Sun exposure protection including
- Limiting time outdoors
- Using sunscreen
- Prevention of medication induced complications
- Screening for osteopenia and osteoporosis
References
- ↑ Aggarwal, Rohit; Rider, Lisa G.; Ruperto, Nicolino; Bayat, Nastaran; Erman, Brian; Feldman, Brian M.; Oddis, Chester V.; Amato, Anthony A.; Chinoy, Hector; Cooper, Robert G.; Dastmalchi, Maryam; Fiorentino, David; Isenberg, David; Katz, James D.; Mammen, Andrew; de Visser, Marianne; Ytterberg, Steven R.; Lundberg, Ingrid E.; Chung, Lorinda; Danko, Katalin; García-De la Torre, Ignacio; Song, Yeong Wook; Villa, Luca; Rinaldi, Mariangela; Rockette, Howard; Lachenbruch, Peter A.; Miller, Frederick W.; Vencovsky, Jiri (2017). "2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheu". Arthritis & Rheumatology. 69 (5): 898–910. doi:10.1002/art.40064. ISSN 2326-5191.
- ↑ Tiniakou, Eleni; Mammen, Andrew L. (2015). "Idiopathic Inflammatory Myopathies and Malignancy: a Comprehensive Review". Clinical Reviews in Allergy & Immunology. 52 (1): 20–33. doi:10.1007/s12016-015-8511-x. ISSN 1080-0549.